Liraglutide's Efficacy for Blood Glucose Control in Type 2 Diabetes Investigated as Add-on Therapy

Type 2 Diabetes (T2D) is a progressive metabolic disorder often requiring escalating therapeutic regimens to maintain adequate glycaemic control. While foundational drugs like metformin and insulin sensitizers such as rosiglitazone are effective, many patients eventually experience treatment failure, necessitating additional agents. This leads to a persistent clinical gap for patients whose HbA1c levels remain elevated despite dual therapy. Liraglutide, a long-acting GLP-1 receptor agonist, offers a multifaceted approach by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, thereby improving glycaemic control and often leading to weight loss. Its potential to complement existing oral agents, particularly in patients already on metformin and a thiazolidinedione like rosiglitazone, represents a critical area of investigation to improve patient outcomes.

A Phase 3, randomized, double-blind trial enrolled 400 subjects with Type 2 Diabetes in the USA and Canada. Participants were already on existing combination therapy with rosiglitazone and metformin. The study was designed to evaluate the effect of adding liraglutide to this regimen, comparing it against continued rosiglitazone and metformin therapy alone. The primary endpoint for this investigation was the effect on blood glucose control, aiming to determine if liraglutide could provide superior glycaemic control in this specific patient population.